DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Funds developing or validating the biomarkers and outcome measures that make ALS clinical trials sharper, not the trials themselves.
About
ALS clinical trials keep stalling for a reason that has nothing to do with the drug: nobody agrees on how to measure whether it's working. This award pays for fixing that measurement problem, not for running a trial itself.
Two related tracks are open. One is biomarkers — identifying, developing or validating a biological signal for ALS risk, diagnosis, disease progression, prognosis, prediction,…
BiotechMedtech
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.